ARTICLE | Clinical News
Anetumab ravtansine: Phase I data
June 13, 2016 7:00 AM UTC
Data from 147 evaluable patients with advanced solid tumors refractory to standard treatment in an open-label, dose-escalation, U.S. Phase I trial showed that the maximum tolerated dose (MTD) of IV an...